Medications for androgenetic alopecia

Chuchai Tanglertsampan

Authors

Chuchai Tanglertsampan DEPARTMENT OF DERMATOLOGY, MAE FAHLUANG UNIVERSITY HOSPITAL, BANGKOK, THAILAND

Keywords:

androgenetic alopecia, hair loss, treatment

Abstract

Androgenetic alopecia (AGA) is the common hair loss in both men and women. Nowadays, many patients with AGA see dermatologists. There are treatments available including medications, hair transplantation and light therapy. This review will emphasis on medical treatments for practicing dermatologists.

References

Tosti A, Piraccini BM. Diagnosis and treatment of hair disorders: an evidence based atlas. London: Taylor & Francis Group; 2006.

Pathomvanich D, Pongratananukul S, Thienthaworn P, Manoshai S. A random study of Asian male androgenetic alopecia in Bangkok, Thailand. DermSurg 2002; 28: 804-7.

Kuster W, Happle R. The inheritance of common baldness: Two B or not two B. J Am Acad Dermatol 1984; 11: 921-6.

Otberg N, Restrepo I, Shapiro J. Possibilities and limitations for reversal of age-related hair loss. In: Trüeb RM, Tobin DJ, editors. Aging hair.New York: Springer; 2010. p.193-206.

Sawaya ME, Price VH. Different levels of 5-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109: 296-300.

Kaufman KD. Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin 1996; 14:697-711.

Price VH. Treatment of hair loss. N Eng J Med 1999;341:964-73.

Schweikert HU, Wilson JD. Regulation of human hair growth by steroid hormones. I. Testosterone metabolism in isolated hairs. J Clin Endocrinol Metab 1974;38:811-9.

Hamilton JB. Male hormone stimulation is prerequisite and an incitantin common baldness. Am J Anat 1942;71:451-80.

Norwood OT. Standard for classification of most common types of male pattern baldness. South Med J 1975;68:1359-65.

Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977;97:247-54.

Olsen EA. Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. J Am Acad Dermatol 2003;48(2):213-62.

Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss : a randomized, double-blind, comparative study. J Med Assoc Thai 2012;95:1312-6.

Otberg N, Shapiro J. Hair growth disorders. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s Dermatology in General Medicine. 8thed. New York: McGraw-Hill; 2012. p.979-1008.

Mehta PK, Mamdani B, Sharsky RM, Mahurkar SD, Dunea G. Severe hypertension. Treatment with minoxidil. JAMA 1975;233(3):249-52.

Roger EN, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008;59:547-66.

Lee WS, Lee HJ. Characteristics of androgenetic alopecia in Asian. Ann Dermatol 2012; 24:243-52.

Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in man. J Am Acad Dermatol 2002;47:377-85.

Lucky AW, Picquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004;50:541-53.

Tsuboi R, Tanaka T, Nishikawa T, Ueki R, Yamada H, Katsuoka K, et al. A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. Eur J Dermatol 2007;17:37-44.

Rietschel RL, Duncan SH. Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. J Am Acad Dermatol 1987;16:677-85.

Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol 2002;46:309-12.

Peluso AM, Misciali C, Vincenzi C, Tosti A. Diffuse hypertrichosis during treatment with 5% topical minoxidil. Br J Dermatol 1997;136:118-20.

Gormley GJ, Stoner E, Bruskewitz RC, et al.The effect of finasteride in men with benign prostate hyperplasis. N Eng J Med 1992;327:1185-91.

Kaufman KD, Olsen EA, Whiting D. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998;39:578-89.

Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999;40:930-7.

Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol 2012;39:27-32.

Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43: 768-76.

Iorizzo M, Vinzenci C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol 2006;142:298-302.

Yeon JH, Jung JY, Choi JW, Kim BJ, et al. 5 mg/day finasteride treatment for normoandrogenetic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol 2011;25:211-4.

สมยศ จารุวิจิตรรัตนา.Diseases of hair and hair follicles.ใน: ปรียา กุลละวณิชย์, ประวิตร พิศาลบุตร, บรรณาธิการ.ตำราโรคผิวหนังในเวชปฏิบัติปัจจุบัน: Dermatology 2010.กรุงเทพฯ:บริษัท โฮลิสติก พับลิชชิ่ง จำกัด; 2548. หน้า 147-204.

Charuwichitratana S, Krisdapong P, Sumethiwit R, Tuchinda C. Randomized double-blind placebo controlled trial in the treatment of male androgenetic alopecia with 0.1% finasteride solution. Jpn J Dermatol 2003;113:881.

Sitticharoenchai P. Clinical evaluation of topical formulation of finasteride in male androgenetic alopecia [dissertation]. Bangkok: Chulalongkorn University; 2006.

Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol 2009;75:47-51.

Mazzarella F, Loconsole F, Cammisa A, Mastrolonardo M, Vena GA. Topical finasteride in the treatment of androgenetic alopecia: preliminary evaluations after a 16-month therapy course. J Dermatol Treat 1997;8:189-92.

Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. The importance of dual 5-alpha reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride vs. finasteride. J Am Acad Dermatol 2006;55:1014-23.

Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol 2010;63:252-8.

Avram MR, Rogers NE. The use of low-level light for hair growth: Part I. J Cosmet Laser Ther 2009; 11: 110-7.